35 results
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
30 Mar 22
Results of Operations and Financial Condition
7:40am
immunodeficiency programs, including OTL-103 in WAS
Refined portfolio and 30% proposed workforce reduction extend cash runway into 2024
BOSTON and LONDON, March … proposed to reduce its current workforce by approximately 30%, which will result in a restructuring charge in 2022. Collectively, the actions announced
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
12 May 22
Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress
7:05am
and proposed workforce reduction announced in March 2022 as well as the completion of activities to support the OTL-200 BLA submission.
Selling … . The decline from 2021 resulted primarily from lower cash and share-based personnel costs from the proposed workforce reduction announced in March 2022
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
31 Mar 20
Other Events
4:08pm
by the current situation. We are in a strong financial position with a geographically dispersed workforce, and I am confident in our ability to swiftly
8-K
EX-99.1
78txq7928561pb 84
4 Aug 22
Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights
7:05am
10-Q
gwxup 2sqm
7 May 20
Quarterly report
4:03pm
DEF 14A
56b7su
29 Apr 20
Definitive proxy
4:02pm
PRE 14A
dpr 8sd19i9
14 Apr 20
Preliminary proxy
4:46pm